Open Orphan has successfully raised capital in an oversubscribed fundraise
Open Orphan Plc has completed an equity placing to raise US$15.5 million to maximize available COVID-19 opportunities and testing.
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses: hVIVO and Venn Life Sciences, and has offices in London, Dublin, Paris and the Netherlands. The company is led by a management team with deep industry and financial experience.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Open Orphan Plc on its oversubscribed equity fundraising of US$15.5 million.
Talk to the deal team
PartnerLondon, United Kingdom
Dutch Star Companies TWO successfully lists in a US$130 million IPO
Dutch Star Companies TWO (DSC2), powered by Oaklins Netherlands, has raised US$130 million and has successfully listed on Euronext Amsterdam with the aim of forming a business combination with a Dutch mid-sized target company.Learn more
Spring has completed an equity raise
The owners and management of Spring have completed a fundraising to support its growth strategy.Learn more
TDK Corporation has divested its medical business HTI Medical to GTCR-backed Resonetics
Hutchinson Technology, Inc., a subsidiary of TDK Corporation, has sold its medical business HTI Medical to Resonetics, a portfolio company of GTCR.Learn more